Skip to main content

Table 1 Burden Assessment Scalea, Aripiprazole Lauroxil Group

From: Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study

 

Baseline

Week 9

Week 25

All patients (observed cases)

 Total score, patients, n

88

53b

43c

  Mean (SD)

40.8 (14.2)

32.7 (13.1)

31.8 (11.9)

  Change from baseline, mean (SD)

–

−8.4 (10.2)

−8.9 (12.4)

Patients who completed 25 weeks of treatmentd

 Total score, patients, n

42

40

42

  Mean (SD)

40.6 (15.1)

33.1 (13.8)

31.7 (12.0)

  Change from baseline, mean (SD)

–

−8.0 (9.8)

−8.9 (12.4)

  1. aRange, 19–76
  2. bData from 52 patients contributed to the change from baseline value at week 9
  3. cData from 42 patients contributed to the change from baseline value at week 25
  4. dAll patients who had Burden Assessment Scale data at baseline and week 25